摘要:
In one aspect, the invention relates to compounds having the formula: (I) wherein: Ar, r, Z, X, R 3 , and R 5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要:
The invention relates to compounds having the formula: (I) wherein: Q, W, Y, Z, r, and Ar are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要:
A polyamide moiety comprising at least one unit of formula I: -β 1 -X 1 -Y 1 -X 3 -X 4 -β 3 - (I) wherein: Y 1 is either X 2 -β 2 or β 2 -X 2 ; β 1 is -R β -CH 2 -NH- β a -, wherein β a is a β-alanine residue and R β is chosen from optionally substituted C 1-7 alkylene, C 1-7 alkenylene and C 1-7 alkynylene groups; β 2 and β 3 are β-alanine residues; and X 1 , X 2 , X 3 and X 4 are independently fragments of formula (II): wherein E is an optionally substituted C 5-6 heteroarylene group.
摘要:
Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure Formula: (I); where Q is Formula: (II); or Formula: (III); and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.
摘要:
Fatty acid amide hydrolase inhibitors of the Formula (I) are provided, wherein R is a heterocyclic or heterocyclic carbonyl moiety and R' is a group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. Pharmaceutical compositions and methods comprising compounds of Formula (I) may be used for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, anxiety, epilepsy, depression, pain, inflammation, appetite disorders, glaucoma and insomnia.
摘要:
This invention relates to compounds with a combination of cannabinoid-CB 1 antagonism and serotonin reuptake inhibition to pharmaceutical compositions containing these compounds, to methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders. In particular the invention relates to compoundsof the general formula (I): wherein the symbols have the meanings given in the specification.
摘要:
The present teachings provide carboxylic amide compounds that can modulate the activity of ion channels in a mammal. The present teachings also provide processes for producing said compounds and their pharmaceutically acceptable salts, hydrates and esters, and methods of treating a pathological condition or disorder, or alleviating a symptom thereof, using said compounds including their pharmaceutically acceptable salts, hydrates and esters. The compounds can be useful in modulating ion channel activity including treating a variety of conditions associated with the abnormal modulation of one or more voltage-gated calcium channels.
摘要:
Compounds of Formula (I) wherein R 1 is aryl, cyclohexyl or heterocyclyl, or (C 1-4 )alkyl substituted by aryl, cyclohexyl or heterocyclyl, R 2 is defined heterocyclyl, R 3 is alkyl, aryl, cyclohexyl or heterocyclyl, or (C 1-4 )alkyl substituted by aryl, cyclohexyl or heterocyclyl, R 4 is H or alkyl, or R 3 and R 4 together with the carbon atom to which they are attached are cycloalkyl fused with aryl, and their use as pharmaceuticals.